m+Medelevator.RU
← Поиск публикаций
BMC oral health · 2025

Non-surgical periodontal therapy with and without hyaluronic acid gel in type 2 diabetic stage-II periodontitis patients: a randomized clinical trial.

СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Al-Abbadi Reem, Shemais Nesma, Nawwar Alaa, Fawzy El-Sayed Karim M

Аннотация

BACKGROUND: The present trial evaluated clinically and radiographically the effect of topically applied hyaluronic acid (HA) gel in conjunction with professional mechanical plaque removal (PMPR) in type 2 diabetic stage-II periodontitis patients.

METHODOLOGY: 26 controlled (HbA1c < 7%) type 2 diabetic stage-II grade B periodontitis patients were included in the current trial and randomly assigned to test (n = 13 patients; PMPR + HA) or control (n = 13; PMPR) groups. At baseline, three- and six-months clinical attachment level (CAL; primary outcome), probing pocket depth (PPD), gingival recession depth (GRD), bleeding on probing (BOP), O'Leary plaque index (PI), HbA1c level, radiographic bone density (RBD) and defect depth (DD; all secondary outcomes) were assessed.

RESULTS: Although CAL, PPD, BOP, PI, DD and RBD independently significantly improved in the PMPR + HA and the PMPR groups (p < 0.05), no significant differences were notable between both groups. HbA1c significantly decreased solely in the PMPR + HA group (p < 0.05).

CONCLUSION: Type 2 diabetic patients with stage-II periodontitis, benefit clinically from PMPR in the presence or absence of adjunctive HA gel application. Interestingly, HA as an adjunct to PMPR significantly improved HbA1c levels in controlled type 2 diabetic stage-II periodontitis patients.

TRIAL REGISTRATION: The study was registered in the US National Institutes of Health Clinical Trials Registry (NCT05543434) in September 2022.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты